Skip to main content
SpringerLink
Log in

The National Lung Health Education Program and Managed Care

The Importance of Early Identification and Intervention in Chronic Obstructive Pulmonary Disease

  • Review Article
  • Published:
Disease Management and Health Outcomes

Abstract

The National Lung Health Education Program (NLHEP) is a new healthcare initiative which encourages the early diagnosis of and intervention in patients who are in the process of developing chronic obstructive pulmonary disease (COPD) and related disorders. COPD is primarily a smoker’s disease. Lung injury is due to proteolytic and oxidative damage early in the course of disease and results in premature loss of lung function, as measured by forced expiratory volume in 1 second (FEV1). Smoking cessation will retard this rate of decline and improve prognosis.

The most common cause of death in patients with early stage COPD is lung cancer. Thus, the possibility of lung cancer should be investigated in patients with early degrees of airflow obstruction. The NLHEP Spirometry Statement encourages testing of all smokers aged over 45 years, and anyone with cough, dyspnea, mucus hypersecretion, or wheeze. The spirometry industry has responded to the NLHEP by developing simple, accurate, reliable, and inexpensive office Spirometers for screening purposes. It is hoped that the widespread use of spirometry will begin to reduce the socioeconomic impact of COPD and related lung cancer. Managed care should endorse the goals and objectives of the NLHEP for the benefit of their patients, and to help contain costs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995 Nov; 152 (5 Pt 2): 77S–121S

    Google Scholar 

  2. Mannino DM, Gagnon RC, Petty TL, et al. Obstructive lung disease and low lung function in adults in the United States. Data from the National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2000 Jun 12; 160(11): 1683–9

    Article  PubMed  CAS  Google Scholar 

  3. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995 Mar; 25(3): 305–13

    Article  PubMed  CAS  Google Scholar 

  4. Johnson CL, Rifkind BM, Sempos CT, et al. Declining serum total cholesterol levels among US adults: the National Health and Nutrition Examination Surveys. JAMA 1993 Jun 16; 269(23): 3002–8

    Article  PubMed  CAS  Google Scholar 

  5. Burrows B, Knudson RJ, Camilli AE, et al. The ‘horse-racing effect’ and predicting decline in forced expiratory volume in one second from screening spirometry. Am Rev Respir Dis 1987 Apr; 135(4): 788–93

    PubMed  CAS  Google Scholar 

  6. Petty TL, Silvers GW, Stanford RE. Mild emphysema is associated with reduced elastic recoil and increased lung size but not with air-flow limitation. Am Rev Respir Dis 1987 Oct; 136(4): 867–71

    Article  PubMed  CAS  Google Scholar 

  7. Vestbo J, Sorensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999 May 29; 353(9167): 1819–23

    Article  PubMed  CAS  Google Scholar 

  8. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994 Nov 16; 272(19): 1497–505

    Article  PubMed  CAS  Google Scholar 

  9. Peto R, Speizer FE, Cochrane AL, et al. The relevance in adults of air-flow obstruction, but not of mucus hypersecretion, to mortality from chronic lung disease. Results from 20 years of prospective observation. Am Rev Respir Dis 1983 Sep; 128(3): 491–500

    PubMed  CAS  Google Scholar 

  10. Bascom R. Differential susceptibility to tobacco smoke: possible mechanisms. Pharmacogenetics 1991 Nov; 1(2): 102–6

    Article  PubMed  CAS  Google Scholar 

  11. Sandford AJ, Weir TD, Pare PD. Genetic risk factors for chronic obstructive pulmonary disease. Eur Respir J 1997 Jun; 10(6): 1380–91

    Article  PubMed  CAS  Google Scholar 

  12. Skillrud DM, Offord KP, Miller RD. Higher risk of lung cancer in chronic obstructive pulmonary disease. A prospective, matched, controlled study. Ann Intern Med 1986 Oct; 105(4): 503–7

    PubMed  CAS  Google Scholar 

  13. Tockman MS, Anthonisen NR, Wright EC, et al. Airways obstruction and the risk for lung cancer. Ann Intern Med 1987 Apr; 106(4): 512–8

    PubMed  CAS  Google Scholar 

  14. Kennedy TC, Proudfoot SP, Franklin WA, et al. Cytopathological analysis of sputum in patients with airflow obstruction and significant smoking histories. Cancer Res 1996 Oct 15; 56(20): 4673–8

    PubMed  CAS  Google Scholar 

  15. Ferguson GT, Enright PL, Buist AS, et al. Office spirometry for lung health assessment in adults. Aconsensus statement from the National Lung Health Education Program. Chest 2000 Apr; 117(4): 1146–61

    Article  PubMed  CAS  Google Scholar 

  16. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999 Jan; 159(1): 179–87

    PubMed  CAS  Google Scholar 

  17. Swanney MP, Jensen RL, Crichton DA, et al. FEV6 is an acceptable surrogate for FVC in the Spirometric diagnosis of airway obstruction and restriction. Am J Respir Crit Care Med 2000 Sept; 162(3): 917–9

    PubMed  CAS  Google Scholar 

  18. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. New Engl J Med 2000 Dec 28; 343(26): 1902–9

    Article  Google Scholar 

  19. Schunemann HJ, Dorn J, Grant BJB, et al. Pulmonary function is a long-term predictor of mortality in the general population. 29-year follow-up of the Buffalo Health Study. Chest 2000 Sep; 118(3): 656–64

    Article  PubMed  CAS  Google Scholar 

  20. Hole DJ, Watt GC, Davey-Smith G, et al. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ 1996 Sept 21; 313(7059): 711–6

    Article  PubMed  CAS  Google Scholar 

  21. The health benefits of smoking cessation: a report of the Surgeon General. US Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. Rockville (MD): Centers for Disease Control, 1990. DHHS publication (CDC) no. 90-8416

  22. The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. A clinical practice guideline for treating tobacco use and dependence. A US Public Health Service report. JAMA 2000 Jun 28; 283(24): 3244–54

    Article  Google Scholar 

  23. Wilson L, Devine EB, Su K. Direct medical costs of chronic obstructive pulmonary disease: chronic bronchitis and emphysema. Respir Med 2000; 94: 204–13

    Article  PubMed  CAS  Google Scholar 

  24. Barnes PJ. Novel approaches and targets for treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999 Nov; 160 (5 Pt 2): 72S–9S

    Google Scholar 

Download references

Acknowledgements

The financial support of the following pharmaceutical manufacturers is acknowledged: Boehringer Ingelheim, Glaxo Wellcome, Inc., 3-M Pharmaceuticals, Roche Laboratories; spirometry manufacturers, ndd Medical Technologies, Mallinckrodt, Inc.; and the Emphysema Foundation.

Author information

Authors and Affiliations

  1. University of Colorado Health Sciences Center, 1850 High Street, Denver, Colorado, CO 80218, USA

    Thomas L. Petty M.D. (a pulmonologist, is a Professor of Medicine)

  2. Rush-Presbyterian/St. Luke’s Medical Center, Chicago, Illinois, USA

    Thomas L. Petty M.D. (a pulmonologist, is a Professor of Medicine)

Authors
  1. Thomas L. Petty M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas L. Petty M.D..

Rights and permissions

Reprints and permissions

About this article

Cite this article

Petty, T.L. The National Lung Health Education Program and Managed Care. Dis-Manage-Health-Outcomes 9, 249–254 (2001). https://doi.org/10.2165/00115677-200109050-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00115677-200109050-00002

Keywords

Search

Navigation